These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 26802468)
1. Dipeptidyl peptidase-4 inhibitor MK-626 restores insulin secretion through enhancing autophagy in high fat diet-induced mice. Liu L; Liu J; Yu X Biochem Biophys Res Commun; 2016 Feb; 470(3):516-520. PubMed ID: 26802468 [TBL] [Abstract][Full Text] [Related]
2. Effects of long-term dipeptidyl peptidase-IV inhibition on body composition and glucose tolerance in high fat diet-fed mice. Liu X; Harada N; Yamane S; Kitajima L; Uchida S; Hamasaki A; Mukai E; Toyoda K; Yamada C; Yamada Y; Seino Y; Inagaki N Life Sci; 2009 Jun; 84(25-26):876-81. PubMed ID: 19358859 [TBL] [Abstract][Full Text] [Related]
3. Tissue expression of DPP-IV in obesity-diabetes and modulatory effects on peptide regulation of insulin secretion. McKillop AM; Stevenson CL; Moran BM; Abdel-Wahab YHA; Flatt PR Peptides; 2018 Feb; 100():165-172. PubMed ID: 29412816 [TBL] [Abstract][Full Text] [Related]
4. Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function. Morita A; Mukai E; Hiratsuka A; Takatani T; Iwanaga T; Lee EY; Miki T Endocrine; 2016 Mar; 51(3):429-39. PubMed ID: 26349938 [TBL] [Abstract][Full Text] [Related]
5. Alogliptin improves endothelial function by promoting autophagy in perivascular adipose tissue of obese mice through a GLP-1-dependent mechanism. Zhu B; Li Y; Mei W; He M; Ding Y; Meng B; Zhao H; Xiang G Vascul Pharmacol; 2019 Apr; 115():55-63. PubMed ID: 30447331 [TBL] [Abstract][Full Text] [Related]
6. Long-term inhibition of dipeptidyl peptidase IV improves glucose tolerance and preserves islet function in mice. Reimer MK; Holst JJ; Ahrén B Eur J Endocrinol; 2002 May; 146(5):717-27. PubMed ID: 11980629 [TBL] [Abstract][Full Text] [Related]
7. A novel dipeptidyl peptidase IV inhibitor DA-1229 ameliorates streptozotocin-induced diabetes by increasing β-cell replication and neogenesis. Cho JM; Jang HW; Cheon H; Jeong YT; Kim DH; Lim YM; Choi SH; Yang EK; Shin CY; Son MH; Kim SH; Kim HJ; Lee MS Diabetes Res Clin Pract; 2011 Jan; 91(1):72-9. PubMed ID: 21093089 [TBL] [Abstract][Full Text] [Related]
8. Chronic administration of voglibose, an alpha-glucosidase inhibitor, increases active glucagon-like peptide-1 levels by increasing its secretion and decreasing dipeptidyl peptidase-4 activity in ob/ob mice. Moritoh Y; Takeuchi K; Hazama M J Pharmacol Exp Ther; 2009 May; 329(2):669-76. PubMed ID: 19208898 [TBL] [Abstract][Full Text] [Related]
9. DPP IV inhibitor suppresses STZ-induced islets injury dependent on activation of the IGFR/Akt/mTOR signaling pathways by GLP-1 in monkeys. Zhang Y; Chen Y; Cheng J; Guo Z; Lu Y; Tian B Biochem Biophys Res Commun; 2015 Jan; 456(1):139-44. PubMed ID: 25446112 [TBL] [Abstract][Full Text] [Related]
10. Glucagon-like peptide-1 and islet lipolysis. Sörhede Winzell M; Ahrén B Horm Metab Res; 2004; 36(11-12):795-803. PubMed ID: 15655711 [TBL] [Abstract][Full Text] [Related]
11. Positive interplay between FFAR4/GPR120, DPP-IV inhibition and GLP-1 in beta cell proliferation and glucose homeostasis in obese high fat fed mice. Owolabi AI; Corbett RC; Flatt PR; McKillop AM Peptides; 2024 Jul; 177():171218. PubMed ID: 38621590 [TBL] [Abstract][Full Text] [Related]
12. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet. Nakaya K; Kubota N; Takamoto I; Kubota T; Katsuyama H; Sato H; Tokuyama K; Hashimoto S; Goto M; Jomori T; Ueki K; Kadowaki T Metabolism; 2013 Jul; 62(7):939-51. PubMed ID: 23790528 [TBL] [Abstract][Full Text] [Related]
13. Ezetimibe stimulates intestinal glucagon-like peptide 1 secretion via the MEK/ERK pathway rather than dipeptidyl peptidase 4 inhibition. Chang E; Kim L; Choi JM; Park SE; Rhee EJ; Lee WY; Oh KW; Park SW; Park DI; Park CY Metabolism; 2015 May; 64(5):633-41. PubMed ID: 25704082 [TBL] [Abstract][Full Text] [Related]
14. MK-626, a dipeptidyl peptidase-4 inhibitor, does not improve the hyperglycemia or hyperinsulinemia of nonobese diabetic MKR mice. Bhattacharjee A; Allister EM; Wheeler MB Can J Physiol Pharmacol; 2012 May; 90(5):663-8. PubMed ID: 22530993 [TBL] [Abstract][Full Text] [Related]
15. Durable islet effects on insulin secretion and protein kinase A expression following exendin-4 treatment of high-fat diet-fed mice. Winzell MS; Ahrén B J Mol Endocrinol; 2008 Feb; 40(2):93-100. PubMed ID: 18234911 [TBL] [Abstract][Full Text] [Related]
16. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males. Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186 [TBL] [Abstract][Full Text] [Related]